Cargando…

Expanding use of new oral anticoagulants

New, non-vitamin K antagonist oral anticoagulants (NOACs) have been developed to overcome the limitations of warfarin. These include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. In the US, rivaroxaban and apixaban are licensed for thromboprop...

Descripción completa

Detalles Bibliográficos
Autor principal: Weitz, Jeffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191267/
https://www.ncbi.nlm.nih.gov/pubmed/25374671
http://dx.doi.org/10.12703/P6-93